Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| §112 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARBER, KIMBERLY | 1 | 73.3% | +14.7% |
| XIAO, YAN | 1 | 67.9% | +51.5% |
| HUTTER, GILLIAN A | 1 | 54.9% | +46.1% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704561 | GENE DELIVERY COMPOSITION COMPRISING NITROGEN-DOPED GRAPHENE QUANTUM DOTS | BARBER, KIMBERLY | 17d overdue |
| 17995273 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING LIPID-PHOTOTHERMAL NANOPARTICLE HAVING ANTIBODY BOUND TO SURFACE | XIAO, YAN | 6d |
| 18042806 | MRI CONTRAST MEDIUM INCLUDING CARBON-13-CONTAINING GRAPHENE QUANTUM DOT AND PREPARATION METHOD THEREFOR | YOUNG, MICAH PAUL | 15d |
| 18042801 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE-19, COMPRISING PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID DERIVATIVES, OPTICAL ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ACTIVE INGREDIENT | HUTTER, GILLIAN A | 21d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1642 | 1 |
| 1625 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704561 | GENE DELIVERY COMPOSITION COMPRISING NITROGEN-DOPED GRAPHENE QUANTUM DOTS | BARBER, KIMBERLY | 1615 | §103 | Non-Final OA | 17d overdue | Pending | Apr 25, 2024 |
| 17995273 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING LIPID-PHOTOTHERMAL NANOPARTICLE HAVING ANTIBODY BOUND TO SURFACE | XIAO, YAN | 1642 | §103 | Non-Final OA | 6d | Pending | Apr 04, 2023 |
| 18042801 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE-19, COMPRISING PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID DERIVATIVES, OPTICAL ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ACTIVE INGREDIENT | HUTTER, GILLIAN A | 1625 | §112 | Non-Final OA | 21d | Pending | Feb 24, 2023 |
| 18042806 | MRI CONTRAST MEDIUM INCLUDING CARBON-13-CONTAINING GRAPHENE QUANTUM DOT AND PREPARATION METHOD THEREFOR | YOUNG, MICAH PAUL | 1618 | §103 | Non-Final OA | 15d | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial